Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.

Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q39976187

about

Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment Modulatory effects of bortezomib on host immune cell functions Natural killer cell biology: an update and future directions NKG2D ligands as therapeutic targets Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma.Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors.Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma.Proteasome regulation of ULBP1 transcription.Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells Combination immune therapies to enhance anti-tumor responses by NK cells.The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma.In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer.Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors.MICA SNPs and the NKG2D system in virus-induced HCC.Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.Impact of natural killer cells on chronic hepatitis C and hepatocellular carcinoma.Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.New twist on the regulation of NKG2D ligand expression.Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway.New prospects on the NKG2D/NKG2DL system for oncology.An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

P2860

Q26753067-F8455EE0-928B-424B-819A-EC1EB95F05F5 Q26795618-7E31DAC4-12E6-4FDD-A7F1-0A5626CDF436 Q26830512-EADD1752-53C3-4A4A-BE2D-62CEE568BADB Q27014888-A31870EF-8FC5-4C82-987A-C5E3523D5E9A Q33909404-0E4F12DC-E83C-4A31-9A51-E2255692829A Q34241208-30B4BDE0-3944-4690-ACCC-4FDAC2D85A3C Q34241771-4654F9FE-C019-4475-8CF6-19EB5EA6920B Q35111983-1D2A3D33-663F-442F-A582-3ED5D2A28298 Q35902972-1B36EACB-A7F2-481A-91BB-2EDF9995B5F0 Q36378038-38CDF97F-A61F-48A0-85CC-EE988FD50481 Q36544872-66557A68-9136-4741-AD86-2DCEC2FC3D5A Q37354071-6EB49305-5952-4FD6-B898-AD16C681626C Q37357720-3BC6B1BD-3731-4F34-B1B3-92A8421A5D8D Q37363932-F017588F-EEC2-464B-85E2-7485B48FF153 Q37408550-1C997BF1-90D3-43A6-BA26-EA574D30FACE Q37622429-4317CE52-9A95-47C5-813C-D27E74675E9A Q37625627-C9E1D3A8-3CDA-4C7D-A164-42A788386F36 Q37702765-D753B984-9212-4984-93D0-79EEE2A9DBD1 Q37923837-1A09E175-EACC-4A36-AB86-47C280C4BD9A Q38255751-79CD3F25-411B-4A77-9E6D-321B2D78005B Q38527482-AC41A5B2-5E06-4D05-B322-63EA4AB4574D Q38635000-CF6AB8F7-DBCF-486D-83F4-CD2972C39D40 Q38670280-582327D9-8CAE-40FB-BED3-D50B74ED7E91 Q38855882-73FB2689-FEC4-4424-9BFB-0FC065FA3922 Q39323511-913298BE-46A7-4110-B5E9-1425C278D3AE Q39381872-E878EDB4-594A-466A-959D-85F7DDAA7099 Q42042886-083AC931-B3D7-43A5-8055-DFAEE970E96A Q42136711-26C47A65-2646-4B64-BA1B-5BAA66A01E12 Q42371577-2BD7FC27-8C81-421E-80CA-03D1C2E88424 Q42796257-4E82FA36-93BF-49E6-B635-FB23F51724E5 Q57257115-06245B69-4B60-413F-9FD3-BE7414E353D3 Q58755253-7CD05976-66CF-41FB-8405-F733E2084814 Q59136966-E103CF17-CEC0-43A5-9ABD-6A81285ADD52

P2860

Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q39976187

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Direct and natural killer cell ...... b in hepatocellular carcinoma.

@en

Direct and natural killer cell ...... b in hepatocellular carcinoma.

@nl

type

label

Direct and natural killer cell ...... b in hepatocellular carcinoma.

@en

Direct and natural killer cell ...... b in hepatocellular carcinoma.

@nl

prefLabel

Direct and natural killer cell ...... b in hepatocellular carcinoma.

@en

Direct and natural killer cell ...... b in hepatocellular carcinoma.

@nl

P1433

Q39976187-2979BADD-9234-4AF3-890D-7E89D1648B5C

P1476

Q39976187-9498FA4D-815B-4A93-BF46-A82AA58443F6

P2093

Q39976187-1D0DE1D1-BE2B-43B2-AF5B-6810E5C4971D

Q39976187-2B101783-E521-4954-983E-34A47D1F0B55

Q39976187-38F4D1FE-E864-4877-BF2B-75FCD6321AA2

Q39976187-444D71EB-5C5F-406F-92AC-292E4BB52F12

Q39976187-827FE532-4216-4EC5-B41B-1F5FCD377913

Q39976187-F83D4332-A723-481C-A2DF-FB96006EDC7F

Q39976187-FD007EB3-9E20-4066-9A32-1DFEA45151FF

P304

Q39976187-CAF3AA47-4F01-40FA-B604-D3BBB7A6EF75

P31

Q39976187-D5277EB2-795A-406A-B3EE-642B4A11B2F2

P356

Q39976187-7417C492-33E8-49ED-BE50-11D5ED261A05

P407

Q39976187-547A2557-C140-45E9-B3A1-9090C8E0BE52

P433

Q39976187-A52523A8-19B4-4658-B2FD-EA7AFC65E571

P478

Q39976187-90DCD34B-9BB1-4001-AC3B-1D4A47DCF4C7

P50

Q39976187-67B52371-2139-4E72-9D4F-6A1700DC2DC4

Q39976187-AFC62EF2-0BD9-4AF6-8E66-4D3BAF81CA00

P577

Q39976187-C20B7F2B-5357-4D96-AD94-E6C55A1177FC

P698

Q39976187-9F2E67A6-7149-462E-93AE-7CAA618C7AF3

P356

1078-0432.CCR-07-4744

P1433

Clinical Cancer Research

P1476

Direct and natural killer cell ...... b in hepatocellular carcinoma.

@en

P2093

Helmut R Salih

http://www.w3.org/2001/XMLSchema#string

Irina Smirnow

http://www.w3.org/2001/XMLSchema#string

Katrin M Baltz

http://www.w3.org/2001/XMLSchema#string

Matthias Krusch

http://www.w3.org/2001/XMLSchema#string

Michael Bitzer

http://www.w3.org/2001/XMLSchema#string

Sorin Armeanu

http://www.w3.org/2001/XMLSchema#string

Ulrich M Lauer

http://www.w3.org/2001/XMLSchema#string

P304

3520-3528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-4744

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Steinle

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18519785

http://www.w3.org/2001/XMLSchema#string